Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.
Nebivolol is a vasodilator that combines beta-adrenergic blocking activity with a relaxant effect on vascular smooth muscle cells (VSMC) mediated by the endothelial nitric oxide (NO) pathway. FFR provide a model of dietary-induced insulin-resistance syndrome, which has been used to study the pathophysiological mechanisms associated with this syndrome. Our main objective was to examine the effect of long-term administration of nebivolol on metabolic and cardiovascular variables in fructose-fed rats (FFR), a model in which an altered bioavailability of NO has been already described. Male Wistar rats were randomly assigned to 4 groups (n = 8 each): I. Control (C); II. Control + nebivolol (C+N): 1 mg/kg(-1) x day(-1) in drinking water during the last 4 weeks. III. FFR: rats receiving fructose in drinking water as a 10% (w/v) solution during 8 weeks, and IV. FFR+N: idem II plus III. During the 8 weeks experimental period, variations in systolic blood pressure (SBP), glucose tolerance test (GTT) and plasma thiobarbituric acid-reactive substances (TBARS) were assessed. At the end of this experimental period, rats were killed and heart and kidneys were excised for calculation of relative heart weight (RHW) and histological evaluation of lumen to media ratio (L/M) in renal arteries. Rats from FFR group increased their SBP and RHW, showed glucose intolerance and an increment in lipid peroxidation. Moreover, FFR showed vascular remodeling in renal arteries evidenced by changes in L/M. Although the metabolic changes were not reverted by the administration of nebivolol, this drug successfully decreased SBP, TBARS levels and reverted structural changes such as cardiac hypertrophy and renal arterial remodeling. Data demonstrate that nebivolol administration could participate in the reversion of cardiovascular structural changes associated with the insulin-resistance syndrome.
Renna
N
N
Dept. of Morphophysiology, School of Medicine, National University of Cuyo and CONICET, Mendoza, Argentina. rmiatell@fcm.uncu.edu.ar
Risler
N
N
Cruzado
M
M
Gonzalez
S
S
Lama
C
C
Miatello
R M
RM
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D006332:Cardiomegaly / Q000473:pathology / Q000503:physiopathology; D004983:Ethanolamines / Q000494:pharmacology*; D005632:Fructose / Q000494:pharmacology; D018149:Glucose Intolerance / Q000097:blood / Q000503:physiopathology; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D007333:Insulin Resistance / Q000502:physiology*; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology; D008297:Male; D023421:Models, Animal; D009206:Myocardium / Q000737:chemistry / Q000473:pathology; D000068577:Nebivolol; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects / Q000502:physiology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012077:Renal Artery / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D001786:Blood Glucose; D004983:Ethanolamines; D017392:Thiobarbituric Acid Reactive Substances; D014665:Vasodilator Agents; D000068577:Nebivolol; D005632:Fructose; D009569:Nitric Oxide